Weâ€™re always talking about the rapid pace of oncology drug development in this era, but perhaps nothing illustrates that trend so clearly as the events of one 15-day period in November.
We’re always talking about the rapid pace of oncology drug development in this era, but perhaps nothing illustrates that trend so clearly as the events of one 15-day period in November.
During that timespan, the FDA approved three new drugs in multiple myeloma including the first-ever monoclonal antibodies for the malignancy and the first oral proteasome inhibitor. That’s on top of another first-in-class drug approved earlier this year. Although there have been advances in new drugs to treat patients with the tumor type over the years, you would probably have to go back about 10 years to find that number of novel agents introduced to the armamentarium.
That snapshot of new drug approvals crystallizes the reasons that we have decided to turn OncologyLive into a publication that reaches your desk twice a month. Quite simply, you cannot afford to wait that long to find out what is going on in your field.
The expanded schedule will enable us to bring our robust mix of oncology information to you more frequently including our unique Physicians’ Education Resource (PER) conference coverage, OncPathways series, and Peer Exchange articles. We’ll also be able to provide more extensive coverage of major oncology meetings held in the United States and internationally.
Editor-in-Chief Maurie Markman, MD, summed up our goals quite succinctly. “OncologyLive will increasingly become the GO TO publication for practicing oncologists and others looking for critical updates and information relevant to the care of patients with malignant disease,” said Markman.
It is not simply the fact that new drugs or treatment regimens are being developed. It is also the realization that these advances are occurring because of scientific discoveries about the underlying biology of cancers. What you need to know as practicing oncology specialists is changing as rapidly and extensively as the new therapy options now available.
So many challenges remain in the oncology field. We would like to hear from you about what you would like to read in the pages of OncologyLive and on our industry-leading website, OncLive.com.
We are excited about being able to bring this publication to you more frequently. We wish you all a happy New Year and, as always, thank you for reading.